Navigation Links
Vitala™ Pouchless Continence Control Device Shown to be Safe and Effective for up to 12 Hours in Phase 3 Clinical Trial
Date:9/28/2011

SKILLMAN, N.J., Sept. 28, 2011 /PRNewswire/ -- Findings from an international Phase 3 clinical trial of the Vitala™ Continence Control Device (CCD) showed the device was safe and effective at restoring continence when worn up to 12 hours per day by people with a colostomy.  In addition, 87% of users rated the ability of the device to restore continence as "good" or "very good," according to the study results published in the British Journal of Nursing.(1)

Developed by ConvaTec, Vitala™ CCD is an innovative, non-invasive device that allows individuals to manage their colostomy without having to wear a pouch or incorporate irrigation. When in use, Vitala™ CCD prevents the uncontrolled release of stool, which is stored inside the body, while permitting gas to vent through an integrated, deodorizing filter.  The unique design also helps reduce noise and odors, and the discreet low profile device helps make the presence of an ostomy less noticeable.(1)

"For people with a colostomy, the loss of continence control gives rise to multiple concerns that can negatively impact their quality of life," said lead study investigator Ann Durnal, RN, BSN, CWOCN. "These findings, which are consistent with those of an earlier Phase 2 study, indicate that this transformational technology can achieve the goal of colostomy continence that has for so long eluded us."

The Phase 3 clinical study, conducted at 16 centers in the U.S. and Europe, evaluated the safety and efficacy of the device when worn up to 12 hours by individuals with an end colostomy for nearly six months.  Participants in the study (n=78) were monitored across a range of treatment stages, including usual pouching (21 days), skin barrier transition (14 days), and device wear (21 days of device ramp-up increasing to 12 hours of daily wear for 159 days).

After the study period of 215 days, results showed that there were no serious adverse events related
'/>"/>

SOURCE ConvaTec
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ConvaTec Presents New Data on ConvaTec Moldable Technology™ and Vitala™ Continence Control Device in Ostomy Care
2. Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee
3. New Data Presented on the Renessa(R) Treatment for Female Stress Urinary Incontinence
4. New Study Reports That Physical Therapy Treatment Resolves Symptoms of Urinary Incontinence in Women
5. New Study Offers More Than a Decade of Evidence for Minimally-Invasive Surgery to Treat Female Incontinence
6. Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
7. Zassi Medical Evolutions Spins out Electrical Stimulation Technology for Gastrointestinal Continence Control and Forms New Company with Technology Investment Firm
8. NanoPowers Raises CHF 5 Million ($4.5 Million) in Series A Financing to Support Development of Breakthrough Urinary Incontinence Device
9. Boston Scientifics Womens Health Products Featured in Studies at the Joint Annual Meeting of the International Continence Society and International Urogynecological Association
10. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
11. FDA Approves Injectable Gel to Treat Fecal Incontinence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
(Date:7/9/2014)... that sudden, acute episodes of low back pain are ... air pressure, wind direction and precipitation. Findings published in ... the American College of Rheumatology (ACR), indicate that the ... wind speed or wind gusts, but was not clinically ... (WHO) nearly everyone experiences low back pain at some ...
(Date:7/9/2014)... Perelman School of Medicine at the University of Pennsylvania ... received an $8 million grant from the National Cancer ... therapy (PDT) in patients with malignant pleural mesothelioma, a ... itself in the lining of the lungs and is ... will fund a clinical trial and additional studies looking ...
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
(Date:7/9/2014)... paint a relatively optimistic picture of women,s chances of ... to the chest wall or skin, but not beyond. ... of size and whether they have involved lymph nodes, ... "locally advanced" tumors, suggesting that they are a relatively ... advanced breast cancers of this and other types account ...
(Date:7/9/2014)... Researchers from The Miriam Hospital have found that ... are also depressed have difficulty sticking to a ... true for women, and screening and brief treatment ... treatment. The study and its findings are published ... , Chronic obstructive pulmonary disease is a common ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... Dec. 29 (HealthDay News) --,Concentrating on music can provide ... significant anxiety, according to a new study. Researchers ... the effectiveness of music as a pain reliever on ... a melody so they could identify the tones that ...
... HealthDay Reporter , THURSDAY, Dec. 29 (HealthDay News) -- ... crushing depression and crippling anxiety to powerful delusions and hallucinations ... the imagined. And if that weren,t enough, they also ... world perceives their inner struggle. Stigma associated with ...
... 29 (HealthDay News) -- In some cases, memory loss among ... research suggests. Such strokes, which may not cause any ... and are found in roughly 25 percent of older adults, ... study of memory loss in the elderly is that it ...
... HealthDay Reporter , WEDNESDAY, Dec. 28 (HealthDay News) -- ... lengthen progression-free survival by about four months for women with ... Avastin (bevacizumab) will make a difference in overall survival. One ... a difference in overall survival between two treatment groups. ...
... West Orange, NJ. December 28, 2011. The 2011 revision ... Spinal Cord Injury (ISNCSCI) was published in the November ... Medicine . The accompanying reference article by Steven Kirshblum ... Both are available for free download via http://www.ingentaconnect.com/content/maney/scm ...
... 2011) Treating ovarian cancer with the drug bevacizumab ("Avastin") ... results of an international clinical trial co-led by Drs. Amit ... and Timothy Perren, St James,s Institute of Oncology, Leeds, UK. ... England Journal of Medicine, report that the drug halted ...
Cached Medicine News:Health News:Even Today, the Stigma of Mental Illness Won't Fade 2Health News:Even Today, the Stigma of Mental Illness Won't Fade 3Health News:'Silent Strokes' Linked to Memory Loss in Elderly: Study 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 2Health News:Avastin May Help Some With Ovarian Cancer: Studies 3Health News:Avastin May Help Some With Ovarian Cancer: Studies 4Health News:JSCM publishes revised International Standards for Neurological Classification of Spinal Cord Injury 2Health News:Ovarian cancer study proves drug delays disease progression, may improve survival 2
... have a direct thermal print surface ... HF-I transponder. When processed through a ... other graphics may be printed at ... programmed to the RFID transponder. Please ...
... The Radianse single-use active-RFID ... and convenience of medical consumables ... of Radianse reusable active-RFID tags. ... patient's ID wrist band, fit ...
... Techno THERM RFID labels are carefully ... materials and RFID antennas. SATO Techno ... and manufactured to ensure optimum performance ... SATO printer / encoders are available ...
PDC Smart® Wrist Tag provides read/write and data storage capabilities....
Medicine Products: